Amryt Pharma PLC ( LON:AMYT ) said the integration of Aegerion Pharmaceuticals is progressing "well" and "ahead of expectations" after its acquisition in September. The AIM-listed firm, which focuses on treatments for rare and orphan diseases, said it had US$60.9mln in the bank as of 16 December, which was "significantly" more than expected after raising US$60mln in September. READ: Amryt Pharma's transformation reflected in nine-month update In line with plans, 28 new positions have been filled to date with additional roles expected to be filled in the first quarter of 2020.